| Entries |
| Document | Title | Date |
|---|
| 20080214782 | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides - The present invention relates to phosphopeptide compositions and anti-phosphopeptide antibody compositions. Also provided are methods of identifying phosphorylation sites in phosphorylated peptides and phosphorylation site motifs. | 09-04-2008 |
| 20080262199 | Protein kinase C peptides for use in withdrawal - A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for εPKC or γPKC and instructions for use. | 10-23-2008 |
| 20080287652 | Antagonists Against Interaction of Pf4 and Rantes - The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment. | 11-20-2008 |
| 20080287653 | METHOD FOR PRODUCING INHIBITORS AND INHIBITORS FORMED THEREFROM - The present invention relates to methods for producing inhibitors for protein deacetylases, and to the compounds and/or products produced by such methods. More specifically, the present invention relates to methods for producing inhibitors for human class III protein deacetylases or sirtuins, and to the compounds and/or products produced by such methods. The present invention provides the transformation of peptide substrates to potent peptide inhibitors by replacement of N | 11-20-2008 |
| 20080312409 | Genetically engineered cDNA of rat bcl-x gene and an improved protein - The present invention provides an genetically engineered cDNA of the rat bcl-x gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat bcl-x cDNA of SEQ ID NO: 1, a recombinant vector containing the engineered cDNA, a cell into which the recombinant vector was introduced, and an improved protein of Bcl-x | 12-18-2008 |
| 20080312410 | Cysteine-containing peptide tag for site-specific conjugation of proteins - The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein. The present invention is also directed to biological sequences employed in the above biological conjugates, as well as pharmaceutical preparations and methods using the above biological conjugates. | 12-18-2008 |
| 20090012261 | HLA Epitope Identification - The present invention describes ways to identify HLA allele-specific epitopes that result from HLA restriction of antigen-specific cellular immune responses. The invention employs a combination of bioinformatics and functional assays to systematically identify and classify CTL mutations to determine correlates of virus-host interactions Peptides representing HLA allele-specific epitopes are provided as well as methods for validating HLA-restricted epitopes and methods for measuring T cell responses. | 01-08-2009 |
| 20090030179 | ANTIMICROBIAL PEPTIDE AND USE THEREOF - Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the α-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein. | 01-29-2009 |
| 20090030180 | Hyaluronic Acid Binding Peptides Enhance Host Defense Against Pathogenic Bacteria - Several species of bacteria capable of invasive infections, such as | 01-29-2009 |
| 20090054622 | Peptide variants of the tumor marker MUC1 and their application - The invention refers to peptide variants of the tumor marker MUC1 and their application in antigenic and immunogenic remedies. It concretely refers to peptide variants of the MUC1 tandem repeat unit within the VNTR (=variable number of tandem repeats) domain. | 02-26-2009 |
| 20090062511 | PROCESS FOR THE PREPARATION OF BIVALIRUDIN AND ITS PHARMACEUTICAL COMPOSITIONS - The present application provides an improved process for the preparation of Bivalirudin and its pharmaceutical compositions. | 03-05-2009 |
| 20090149631 | Methods and compositions for protein labeling using lipoic acid ligases - The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ lipoic acid ligase or mutants thereof, and lipoic acid analogs recognized by lipoic acid ligase and lipoic acid ligase mutants. | 06-11-2009 |
| 20090149632 | Antibacterial peptide - The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also provides for a peptide comprised of a sequence of cationic and non-polar or polar uncharged amino acids forming an α-helix wherein the amino acids are arranged along the α-helix such that when represented as a helical wheel, there is a substantial bi-lateral symmetry between cationic versus non-polar or polar uncharged amino acids. | 06-11-2009 |
| 20090176964 | Stabilized Alpha Helical Peptides and Uses Thereof - Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death. | 07-09-2009 |
| 20090176965 | Sericin Having Improved Antioxidant and Tyrosinase Inhibitive Abilities by Irradiation, and Methods of Making and Using the Same - Disclosed are sericin having improved antioxidant and tyrosinase inhibitory abilities and increased molecular weight by irradiation, which causes a modification of a sericin molecular structure, a preparation method thereof and use of the irradiated sericin in various applications including food products, cosmetics and/or pharmaceutical products and medicines to improve antioxidant ability and/or tyrosinase inhibitory functions. | 07-09-2009 |
| 20090203879 | ACTIVATED LABELING REAGENTS AND METHODS FOR PREPARING AND USING THE SAME - The present invention relates in general to labeling reagents useful for labeling biomolecules. In particular, the invention provides activated labeling reagents, methods of preparing the same, methods of using the labeled reagents for synthesizing a labeled biomolecule, kits that include reagents for a labeling a biomolecule and kits containing for labeled biomolecules. | 08-13-2009 |
| 20090292108 | Insulinotropic peptide synthesis using solid and solution phase combination techniques - The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to add additional amino acid material to the third fragment which is then coupled to the second fragment and then the first fragment in solution. Alternatively, a different second fragment is coupled to the first fragment in the solid phase. Then, solution phase chemistry is then used to add additional amino acid material to a different third fragment. Subsequently, this different third fragment is coupled to the coupled first and different second fragment in the solution phase. The use of a pseudoproline in one of the fragments eases solid phase synthesis of that fragment and also eases subsequent solution phase coupling of this fragment to the other fragments. The present invention is very useful for forming insulinotropic peptides such as GLP-1(7-36) and its natural and non-natural counterparts. | 11-26-2009 |
| 20090326197 | IFBM's to Promote the Specific Attachment of Target Analytes to the Surface of Orthopedic Implants - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-31-2009 |
| 20090326198 | IFBM's to Promote the Specific Attachment of Target Analytes to the Surface of Orthopedic Implants - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-31-2009 |
| 20090326199 | IFBM's to Promote the Specific Attachment of Target Analytes to the Surface of Orthopedic Implants - implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-31-2009 |
| 20100016548 | Self-assembling peptide and gel produced from the same - A self-assembling peptide containing a polar amino acid residue and a nonpolar amino acid residue, wherein the self-assembling peptide contains an acidic amino acid residue and a basic amino acid residue as the polar amino acid residues, a total sum of charge of the acidic amino acid residue and charge of the basic amino acid residue in a neutral region is the number excluding 0, and the self-assembling peptide is capable of forming a beta (β)-sheet structure in which only the nonpolar amino acid residue is arranged on one face upon self-assembly in an aqueous solution. | 01-21-2010 |
| 20100036091 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 02-11-2010 |
| 20100048864 | BACTERIAL LEADER SEQUENCES FOR INCREASED EXPRESSION - Compositions and methods for improving expression and/or secretion of a polypeptide of interest in a host cell are provided. Compositions including a coding sequence for a bacterial secretion signal peptide are provided. The compositions of the invention are useful for increasing accumulation of properly processed proteins in the periplasmic space of a host cell, or for increasing secretion of properly processed proteins. In particular, isolated secretion signal peptide-encoding nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the nucleic acid molecules are encompassed. The present invention provides for isolated nucleic acid molecules including nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24, and the nucleotide sequences set forth in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, as well as variants and fragments thereof. | 02-25-2010 |
| 20100056755 | Process for Making Bivalirudin - The present invention relates to the efficient commercial synthesis of Bivalirudin. | 03-04-2010 |
| 20100222547 | Integrated Photoactive Peptides and Uses Thereof - This invention is directed to the general method of transforming bioactive compounds of known structure and function into photoactive molecules such that the original biological activity is retained. The molecules resulting from the integration of two fundamental properties of photoactivity and biological function into a single molecular entity are hereinafter generally referred to as ‘integrated photoactive analogs’ or ‘integrated photoactive peptides or pseudopeptides.” The general method for the design of integrated photoactive analogs principally involves: (a) selecting a desired bioactive peptide or pseudopeptide; (b) identifying the region of the molecule that contains an aromatic or a heteroaromatic motif; and (c) either replacing said motif with a photoactive functional group of similar size, or modifying said motif to render it photoactive. Other aspects include photoactive analog compounds and photodiagnostic and phototherapeutic uses thereof. | 09-02-2010 |
| 20100273982 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 10-28-2010 |
| 20100273983 | METHOD OF PURIFYING PEPTIDES BY SELECTIVE PRECIPITATION - A method is provided for purifying peptides by selective precipitation of contaminating proteins, such as host cell proteins and cleaved fusion partners. Also provided is a method of cleaving fusion proteins in cell lysates. | 10-28-2010 |
| 20100286367 | CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS - The present invention provides, among other things, soluble derivatives of soluble polypeptides that incorporate membrane binding elements. Methods of making these soluble derivatives, and methods of using these soluble derivatives also are provided. | 11-11-2010 |
| 20100292436 | METHOD FOR PRODUCING BIVALIRUDIN - A method for producing bivalirudin using solid phase peptide synthesis by the following steps: a) mixing a Fmoc-amino acid resin or a Fmoc-peptide resin with a de-protective agent so as to remove Fmoc-; b) in the presence of a condensing agent, condensing a Fmoc- or Boc-amino acid with the amino acid or the peptide bound to the resin; c) repeating the steps a) and b) to yield a peptide resin represented by Formula I, | 11-18-2010 |
| 20100298536 | COMPLEX OF CELL TRANSLOCATIONAL PEPTIDE AND MAGNETIC NANOPARTICLES AND USE THEREOF - The present invention relates to a cell-penetrating peptide/fluorescence-labeled magnetic nanoparticle complex and the use thereof. More specifically, relates to a cell-penetrating peptide/fluorescence-labeled magnetic nanoparticle complex in which a cell-penetrating peptide is chemically linked to a fluorescence-labeled magnetic nanoparticle, such that fluorescence-labeled magnetic nanoparticle can be stably introduced directly into cells without endocytosis, and a composition for cell imaging containing the complex. The disclosed invention suggests an innovative therapeutic technology which shows high stability, maximizes the effect of imaging diagnosis through optimal targeting and minimizes side effects, unlike existing viral peptide transporters. | 11-25-2010 |
| 20100317828 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-16-2010 |
| 20100317829 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-16-2010 |
| 20100324262 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-23-2010 |
| 20100324263 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-23-2010 |
| 20100331518 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-30-2010 |
| 20100331519 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 12-30-2010 |
| 20110040071 | Protein Kinase-Inducible Domains - Applicants have used protein design to develop novel functional protein architectures, termed protein kinase-inducible domains, whose structures are dependent on phosphorylation by specific protein kinases or are dependent on dephosphorylation by specific protein phosphatases. Applicants have designed kinase-inducible domains based on a modular architecture, which allows kinase-inducible domains to be responsive to any specific serine-threonine kinases. Kinase-inducible domains can consist of canonical amino acids, allowing their use as expressible tags of protein kinase activity. | 02-17-2011 |
| 20110082280 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules - Methods of coupling targeting molecules to multidentate aza ligands of general formula (I): | 04-07-2011 |
| 20110124842 | Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom - The present invention relates to the structure of Fab 4E10, e.g., as a complex with herein identified peptide KGND, herein identified as a 4E10 mimetope on gp41, as determined by crystallographic techniques, and the confirmation that peptide KGND has a functional relevant conformation, as well as the determination of key residues on 4E10, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides which bind to Fab 4E10. | 05-26-2011 |
| 20110160431 | PRODUCTION OF PEPTIDES CONTAINING POLY-GLY SEQUENCES USING FMOC CHEMISTRY - A peptide containing a poly-Gly sequence, such as bivalirudin, can be prepared in a purified form in which low amounts of GIy deletion or GIy addition byproducts are present. A protected poly-Gly-containing peptide is attached to a resin using Fmoc-Gly-GIy-OH units for assembly of the poly-Gly segment. The protected peptide is then cleaved from the resin with an acidic composition to produce an unprotected or semi-protected crude peptide, which can then be isolated from acidic composition. | 06-30-2011 |
| 20110160432 | MYOCARDIAL PEPTIDE, PREPARATION METHOD AND USES THEREOF - Disclosed are two myocardial peptides, whose amino acid sequences are Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe and Lys-Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe respectively, wherein the latter can be obtained by extracting from myocardial peptides solution. The myocardial peptides can be used in the produce of a medicament for preventing and/or treating myocardial ischemia. | 06-30-2011 |
| 20110166322 | ALPHA-CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. | 07-07-2011 |
| 20110178269 | Coronavirus S Peptides - Isolated polypeptides containing SEQ ID NO: 3 and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 07-21-2011 |
| 20110190474 | ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES - The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence. | 08-04-2011 |
| 20110213122 | OBTAINING COCOA EXTRACTS RICH IN BIOACTIVE PEPTIDES WITH ACE AND PEP ENZYME INHIBITORY ACTIVITY - The present invention relates to obtaining bioactive peptides from plant raw materials, specifically cocoa extracts, by means of enzyme treatment. Said biopeptides have angiotensin converting enzyme (ACE) and prolyl endopeptidase enzyme (PEP) inhibitory activity in vitro and/or antioxidant activity in vivo, being able to be used in the food, dietetic and pharmaceutical industry. | 09-01-2011 |
| 20110251372 | PROCESS FOR THE PRODUCTION OF BIVALIRUDIN - The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-D-Phe | 10-13-2011 |
| 20110263816 | METALLOPEPTIDE CATALYSTS - This application provides a metallopeptide catalyst comprising dirhodium bound to one or more carboxylate residues of a peptide, protein or peptidomimetic. These stable metallopeptides can achieve structure-selective protein modification though molecular recognition. | 10-27-2011 |
| 20110269937 | Conserved-Element Vaccines and Methods for Designing Conserved-Element Vaccines - Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such as concatenated polypeptide sequences that together represent a pathogen proteome, corresponding to an observed set of pathogen variants, and computationally selecting conserved subsequences according to a number of subsequence-selection criteria. These subsequence-selection criteria may include a minimum conserved-subsequence length, a threshold frequency of occurrence of a particular monomer at each conserved, single-monomer position within a conserved subsequence, a threshold combined occurrence for a set of allowable variant monomers at a particular conserved, variable position within a conserved subsequence, and a maximum number of variable positions within a subsequence. A set of conserved subsequences identified according to the subsequence-selection criteria are then filtered to remove subsequences identical to, or too similar to, naturally-occurring host subsequences, and are then assembled into expression vectors for incorporation into microbial hosts for biosynthesis of a recombinant CEVac or assembled into one or more synthetic constructs for a synthetic CEVac. | 11-03-2011 |
| 20110275788 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 11-10-2011 |
| 20110306750 | ANTIMICROBIAL PEPTIDE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 12-15-2011 |
| 20110319594 | METHOD FOR PRODUCING BIVALIRUDIN - A method for producing bivalirudin using solid phase peptide synthesis by: a) condensing Fmoc-Asn(Trt)-Gly-OH with a peptide resin of Asp(OtBu) | 12-29-2011 |
| 20120022228 | PURIFICATION OF AMPHOTERIC PRODUCTS, OR OF PRODUCTS LIABLE TO BE CONVERTED INTO AMPHOTERIC PRODUCTS - A process for purifying at least one product from a substrate containing at least one product, includes subjecting the substrate to centrifugal partition chromatography in an ion exchange displacement mode to purify the at least one product from the substrate, the at least one product being an amphoteric product. | 01-26-2012 |
| 20120046444 | PEPTIDE NETWORKS - Methods of modulating interfacial characteristics in a self-assembled, force-transmitting peptide network at a fluid-fluid interface are disclosed. The methods involve exposing a peptide capable of participating in a self-assembled, force-transmitting peptide network, either before or after it interacts with other peptides to form the peptide network to a stimulus that alters the chemical and/or physical properties of the peptide. Use of such methods in applications such as emulsions and foams are also disclosed. | 02-23-2012 |
| 20120071628 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE - Disclosed is a topical therapeutic agent for ophthalmic diseases, which comprises a compound capable of binding specifically to a DNA sequence. More preferably disclosed is a topical therapeutic agent for ophthalmic diseases, which comprise a pyrrole-imidazole polyamide having a specific structure. The topical therapeutic agent for ophthalmic diseases comprises a pyrrole-imidazole polyamide which can inhibit transforming growth factor-β gene and matrix metalloproteinase 9 gene. | 03-22-2012 |
| 20120165506 | NOVEL MEMBERS OF THE CAPSAICIN/VANILLOID RECEPTOR FAMILY OF PROTEINS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 06-28-2012 |
| 20120178901 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 07-12-2012 |
| 20120226019 | COMPOUNDS AND METHODS FOR PURIFYING PEPTIDES PRODUCED BY SOLID PHASE PEPTIDE SYNTHESIS - The invention relates to compounds which can be used for purifying peptides produced by solid phase peptide synthesis. In addition, the invention relates to methods for purifying peptides produced by solid phase peptide synthesis using the compounds according to the invention. | 09-06-2012 |
| 20120232249 | METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME - There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilising the agents. The methods are particularly suitable for inhibiting the growth of cancer cells. | 09-13-2012 |
| 20120259091 | Apolipoprotein A1 Mimetics and Uses Thereof - The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol. | 10-11-2012 |
| 20120264912 | SELF-ASSEMBLING PEPTIDE AMPHIPHILES AND RELATED METHODS FOR GROWTH FACTOR DELIVERY - Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use. | 10-18-2012 |
| 20120271034 | ANTIGENIC DETERMINANTS RECOGNIZED BY ANTI-HUMAN DEATH RECEPTOR DR5 MONOCLONAL ANTIBODY AD5-10, DERIVATIVES AND USES THEREOF - Provided are antigenic determinants recognized by anti-human death receptor DR5 monoclonal antibody AD5-10, derivatives and uses thereof. The antigenic determinants have the amino acid sequence of LITQQDLAPAARA, wherein the core polypeptide is QDLAP. The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants and derivatives thereof can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine. Their nucleotide encoding sequences can be used for preparing antisense nucleotides and small molecular ribonucleotides for treating and preventing tumor and/or AIDS and the like. | 10-25-2012 |
| 20120322977 | Micropatterned multifunctional inorganic nanoparticle arrays based on patterned peptide constructs - An inorganic nanoparticle array is self-assembled onto an unpatterned or patterned, peptide-functionalized substrate surface using peptide constructs comprising a substrate-binding peptide and a mineralization peptide. | 12-20-2012 |
| 20130005943 | Methods for Preparing Internally Constrained Peptides and Peptidomimetics - The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 3 | 01-03-2013 |
| 20130005944 | CXCR4 Receptor Compounds - The invention relates generally to compounds which are allosteric modulators {e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CXCR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow transplantation, chemosensitization, cancer, metastatic disease (e.g., cancer), auto-immune disease (e.g., rheumatoid arthritis), fibrosis disease (e.g., pulmonary), AIDS infection, cardiovascular disease, uveitis, inflammatory diseases, celiac disease HIV infection and stem cell-based regenerative medicine. | 01-03-2013 |
| 20130012685 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 01-10-2013 |
| 20130030152 | TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species. | 01-31-2013 |
| 20130072660 | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER - Disclosed are compositions relating to novopeptides identified by the presence of framshift mutations in tumor genes previously not identified as being oncogenic. The disclosed peptides can be used in the disclosed methods for the treatment of cancer. | 03-21-2013 |
| 20130079493 | Method for prepairing peptide inhibitors of a lipid-activated enzyme and peptides produced by same - The present invention is based on the discovery of a mechanism mediating the formation of amyloid-type aggregates of lipid-activated enzymes. The invention discloses a method for preparing inhibitors of said enzymes and provides peptide inhibitors having potential for therapeutic use. The method comprises the identification of aggregation-prone regions in the amino acid sequence of the enzyme by the use of a suitable computer algorithm and designing a peptide based on the found aggregation-prone region. | 03-28-2013 |
| 20130116406 | BORRELIA ANTIGENS - The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from | 05-09-2013 |
| 20130131313 | EEF2K ASSAYS FOR IDENTIFYING COMPOUNDS THAT INHIBIT EEF2K ACTIVITY - Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein. | 05-23-2013 |
| 20130158234 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 06-20-2013 |
| 20130165629 | BISPECIFIC T-CELL ACTIVATOR ANTIBODY - This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity. | 06-27-2013 |
| 20130217858 | COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY - The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members. | 08-22-2013 |
| 20130231459 | APOLIPOPROTEIN A-I MIMICS - Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder. | 09-05-2013 |
| 20130289237 | USE OF A NEW GENE CODING FOR A NEW MEMBER OF THE MCM2-8 FAMILY IN PHARMACEUTICAL COMPOSITIONS - An isolated antibody specifically binding the C-terminus part of the MCM9 protein, the C-terminus part of the MCM9 protein is one of the following sequences: the amino acids sequence from the position 391 to the position 1143 of the MCM9 proteins of the sequence as set forth in SEQ ID NO: 2 or 16, or the amino acids sequence from the position 391 to the position 1143 of the MCM9 protein of the sequence as set forth in SEQ ID NO: 8. | 10-31-2013 |
| 20140011979 | STITCHED POLYPEPTIDES - The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides. | 01-09-2014 |
| 20140018520 | ANTIFUNGAL PLANT PROTEINS AND METHODS OF THEIR USE - DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described. | 01-16-2014 |
| 20140128570 | CONFORMATIONALLY-PREORGANIZED, MINIPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS - The present invention relates to γ-PNA monomers according to Formula I where substituent groups R | 05-08-2014 |
| 20140135477 | MULTILIGAND CONSTRUCTS - Multiligand constructs and intermediate multivalent constructs for use in their preparation are described. The multiligand constructs have utility in diagnostic and therapeutic applications. | 05-15-2014 |
| 20140142278 | Methods For Producing Secreted Polypeptides Having Biological Activity - The present invention relates to methods for producing a polypeptide having biological activity, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first polynucleotide encoding the polypeptide operably linked to a second polynucleotide encoding a variant signal peptide or a variant prepropeptide; and (b) isolating the secreted polypeptide having biological activity from the cultivation medium. | 05-22-2014 |
| 20140155576 | F11 RECEPTOR (F11R) ANTAGONISTS AS THERAPEUTIC AGENTS - The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal. | 06-05-2014 |
| 20140163202 | Phoenixin Peptides - Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca | 06-12-2014 |
| 20140179900 | TREATMENT OF ATHEROSCLEROSIS WITH CHOLESTEROL ESTER TRANSPORT PROTEIN MIMOTOPES - The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae. | 06-26-2014 |
| 20140187745 | METHOD FOR PREPARING BIVALIRUDIN - A method for preparing bivalirudin. The method includes preparing a bivalirudin resin by a solid phase synthesis, performing acidolysis of the bivalirudin resin to obtain crude bivalirudin, and purifying the crude bivalirudin to obtain purified bivalirudin. The solid phase synthesis method includes successively coupling Fmoc-protected amino acids corresponding to a sequence represented by SEQ. ID NO. 2 on an Fmoc-Leu-carrier resin through solid phase coupling synthesis to obtain the bivalirudin resin represented by SEQ. ID NO. 2. | 07-03-2014 |
| 20140194594 | SYNTHETIC PEPTIDES AND PEPTIDE MIMETICS - The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics. | 07-10-2014 |
| 20140221609 | Activation of Sodium Potassium ATPase - Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase. | 08-07-2014 |
| 20140275479 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 09-18-2014 |
| 20140296481 | Diagnosis and Monitoring of Renal Failure Using Peptide Biomarkers - Methods for the determination of renal failure, especially chronic renal failure and acute kidney injury, by measurement of peptide or protein biomarkers are described. The methods are useful to determine stages of renal failure, especially the early stages such as stage 1, 2, and 3 of chronic renal failure and stages R and I of acute kidney injury. Furthermore there are described peptides and test kits used in the invention. The described methods are intended to replace or complement the measurement of creatinine and/or cystatin C and/or NGAL for diagnosis of renal failure. | 10-02-2014 |
| 20140296482 | METHOD TO SCREEN FOR SELECTIVE PEPTIDES THAT INHIBIT THE BIOLOGICAL ACTIVITY OF CALCINEURIN - The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors and serve as a base for the preparation of therapeutic compositions for the prophylactics and treatment of human diseases associated with T-lymphocyte activation, including, but not limited to, autoimmune diseases, inflammation and allergy or transplant rejections. In addition, said peptides and the associated biological and genetic material can form useful tools for the development of tests that can be used to find compounds that have a selective antagonist activity in relation to CN. | 10-02-2014 |
| 20140343249 | CELL KILLING FUSION PEPTIDE EXHIBITING TUMOR CELL-SPECIFIC NECROSIS INDUCTION AND TUMOR REGRESSION - A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug. | 11-20-2014 |
| 20150011729 | NUCLEOTIDE REPEAT EXPANSION-ASSOCIATED POLYPEPTIDES AND USES THEREOF - Isolated polypeptides that are endogenously expressed from nucleotide repeat expansions are disclosed. In some cases, the polypeptides include polypeptide repeats. In some cases, the polypeptide repeats include at least five contiguous repeats of a single amino acid. In other cases, the repeats include at least six contiguous amino acids of a tetra- or penta-amino acid repeat block. | 01-08-2015 |
| 20150018519 | PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA- THIOESTERS FOR PROTEIN SYNTHESIS - The subject matter of the present invention is peptide C | 01-15-2015 |
| 20150025221 | Skin Permeating and Cell Entering (SPACE) Peptides and Methods of Use Thereof - The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells. | 01-22-2015 |
| 20150031853 | METHOD FOR THE SELECTIVE ENRICHMENT AND LABELING OF PHOSPHORPROTEINS - The embodiments of the invention relate to a method for the introduction of a labeling structure such as a fluorescent molecules or a Raman tags to a compound. Imidazole functionalized resins or polymers are used to selectively immobilize phosphocompounds without protecting the carboxylic groups. Relying on the pKa difference between amines and hydrazides and carrying out the reaction in a slightly acidic buffer, all of the amines are protected by protonation while the hydrazides react with the phosphate imidazolide to form a phosphoramidate bond. | 01-29-2015 |
| 20150038676 | Biologically Active Peptides - A peptide or peptide derivative comprising:
| 02-05-2015 |
| 20150057430 | COMPOUND, USE AND METHOD - The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual. In addition, the invention provides methods of identifying and/or using antagonists of kisspeptin and/or the defined peptides, and pharmaceutical compositions thereof. | 02-26-2015 |
| 20150057431 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS - The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. | 02-26-2015 |
| 20150080550 | Process for the Production of Bivalirudin - The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula | 03-19-2015 |
| 20150112042 | Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 04-23-2015 |
| 20150133633 | MODIFICATION OF PEPTIDES USING A BIS(THIOETHER)ARYLBRIDGE APPROACH - This invention provides novel methods of stabilizing peptides and peptides so stabilized. In certain embodiments the methods involve providing a peptide containing at least two S bearing residues within the peptide; and reacting the peptide with a di-halogen-aryl-compounds to form a bis(thioether)-aryl-bridge between said two residues. | 05-14-2015 |
| 20150291663 | NEW PEPTIDES AS A MONOTHERAPY IN MALIGNANCY CONTROL - Peptides with sequences either in whole or in part or similar sequences as a monotherapy for cancer control, that is, without any need for conventional methods except for diagnosis. Any one or more of the peptides from N Terminus to C Terminus can be used as a drug in malignancy control and management. | 10-15-2015 |
| 20150322113 | ANTI-MICROBIAL ACTIVITY OF SYNTHETIC PEPTIDES - Isolated synthetic peptides are disclosed that have anti-microbial activity against | 11-12-2015 |
| 20150344524 | MODIFIED APIDAECIN DERIVATIVES AS ANTIBIOTIC PEPTIDES - This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to compositions and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as | 12-03-2015 |
| 20150359899 | MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS - This invention relates to a peptide or polypeptide (a) which is esterified or thio-esterified (i) at the carboxylate of the C-terminus with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (ii) at a side-chain carboxylate of one or more Asp or Glu residues, if present, with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (iii) at a hydroxyl group of one or more Ser, Thr or Tyr residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; (iv) at a sulfhydryl group of one or more Cys residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; and/or (v) at the N-terminus with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group, wherein said N-terminus is previously amidated with an alpha- or beta-hydroxy acid, and wherein the ester is formed between the hydroxy group of said alpha- or beta-hydroxy acid and the carboxylic group of said guanidinium alkanoic acid or said PEG substituted with a guanidinium group and a carboxyl group; and/or (b) which contains one or more disulfides, the disulfide being formed between the sulfhydryl group of a Cys reside, if present, and a guanidinium alkanethiol or a PEG substituted with a guanidinium group and a sulfhydryl group. | 12-17-2015 |
| 20160022875 | BONE SUBSTITUTES GRAFTED BY MIMETIC PEPTIDES OF HUMAN BMP 2 PROTEIN - A bone substitute material for bone and dental surgery, includes: i) a solid support made from at least one phosphocalcic compound having free hydroxyl groups on the surface, and ii) a quantity of a mimetic peptide of human BMP-2 protein, having a sequence KX | 01-28-2016 |
| 20160046672 | STAPLING eIF4E INTERACTING PEPTIDES - The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides. | 02-18-2016 |
| 20160096874 | MRG RECEPTOR MODULATORS - The present invention is in the field of molecular biology, more particularly, the present invention relates to drug screening, assay development and identification and use of modulators for G-protein coupled receptor/ligand pair MRGX2/CXCL14 within drug discovery. | 04-07-2016 |
| 20160153987 | Mycobacterium Antigens | 06-02-2016 |
| 20160185821 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES - The invention relates generally to the synthesis of modified amino acids and modified peptides in the presence of cyclometalated catalysts. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry. | 06-30-2016 |
| 20160199504 | Development of Novel Macromolecule Transduction Domain with Improved Cell Permeability and Method for Using Same | 07-14-2016 |
| 20170233445 | ANTI-MICROBIAL PEPTIDE AND METHOD FOR TREATING MICROBIAL INFECTION | 08-17-2017 |
